AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Morgan Stanley on Amgen (AMGN): 'We believe the acquisition will be viewed as a modest positive'
August 4, 2022 10:03 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $253.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We believe the acquisition will be viewed as a modest positive given investors are looking for mgt. to expand the pipeline and near-term revenues.... More
ChemoCentryx (CCXI) to Resume Trading at 8:30 a.m.
August 4, 2022 8:07 AM EDTChemoCentryx (NASDAQ: CCXI) to Resume Trading at 8:30 a.m.
... More